When was NeuroDawn founded?

NeuroDawn was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is NeuroDawn located?

NeuroDawn is headquartered in China.

Is NeuroDawn a funded company?

NeuroDawn is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Aug 23, 2021.

When was the latest funding round of NeuroDawn?

NeuroDawn's latest funding was a $***** Series A round on Aug 23, 2021, with participation from 3 investors. Its primary sector is Neurology. In China, the Neurology sector has seen $229M in funding in 2026 to date.

Where does NeuroDawn rank among its competitors?

NeuroDawn ranks 2054th amongst 2934 active competitors, of which 977 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of NeuroDawn?

NeuroDawn's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

NeuroDawn - 2026 Company Profile, Funding & Competitors

Most viewed in 2019

NeuroDawn is a deadpooled company based in China, founded in 2021. It operates as a Developer of therapeutics for central nervous system diseases. NeuroDawn has raised $10.8M in funding. The company has 2934 active competitors, including 977 funded and 717 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Key Metrics

Founded Year

2021

Location

China

Stage

Deadpooled

Total Funding

$10.8M in 1 round

Latest Funding Round

Series A, Aug 23, 2021, $*****

Investors

Simcere Pharma & 2 more

Ranked

2054^th among 2934 active competitors

Similar Companies

Jazz Pharmaceuticals & 607 more

View NeuroDawn's full profile

NeuroDawn has raised a total funding of $10.8M over 1 round. Its latest funding round was a Series A round on Aug 23, 2021 for $*****. 3 investors participated in its latest round. NeuroDawn has 3 institutional investors.

Here is the list of recent funding rounds of NeuroDawn:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 23, 2021	6058124	Series A	8871997	4533533	2323463	1670860

Access funding benchmarks and valuations. Sign up today!

View details of NeuroDawn's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuroDawn include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of NeuroDawn, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	77/100
4th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
10th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
2054th	NeuroDawn 2021, China, Deadpooled	Developer of therapeutics for central nervous system diseases	$10.8M	Simcere Pharma, Balancing Capital & 1 others	25/100